原始出處紀錄
重大申請已送件
Inhibrx 計畫於 2026 年第二季初提交 ozekibart 的 BLA
該公司表示將於 2026 年第二季初提交 ozekibart 用於無法切除或轉移性傳統軟骨肉瘤的 BLA。同時預計 2026 年第二季公布大腸癌擴展群組的 PFS 數據，並於 2026 年下半年與 FDA 會面，討論在尤因氏肉瘤及第四線大腸癌加速核准事宜。
關鍵事實
- 申報時間
- 2026年3月19日 下午08:01
- 事件
- 申請已送件
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 exhibit99112312025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results San Diego, CA, March 19, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. (the “Acquirer”) and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Upcoming Milestones • ozekibart (INBRX-109) ◦ We expect to submit the Biologics License Application (“BLA”) for ozekibart for the treatment of unresectable or metastatic conventi